Editorial theme | Latest advances in microbiome interventions

This article summarizes talks and posters presented at the virtual 46th Annual Meeting of the European Society for Blood and Marrow...

The impact of JAK inhibitor use on HSCT outcome in patients with MPN

Barabanshikova and colleagues analyzed outcomes of patients with MPN undergoing allo-HSCT with or without prior JAK inhibitor...

KD025 for chronic GvHD: an update

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT) two posters were presented by Madan Jagasia on KD025 (belumosudil).

How should antibiotics be administered in transplant patients to reduce GvHD?

During the 46th Annual Meeting of the European Society for Blood and Marrow Transplantation (EBMT), the GvHD Hub spoke to...

Role of the type 2 cannabinoid receptor in GvHD

Cheng Yin Yuan and colleagues implemented a pre-clinical study to define the role of CB2R in acute and chronic GvHD (a/cGvHD) development and to...

Prolactin as a biomarker for chronic GvHD

Maria Queralt Salas and colleagues investigated if prolactin can be used as a biomarker for chronic GvHD (cGvHD) activity. The results of this retrospective...

The role of the microbiome in the pathogenesis and severity of GvHD

Sarah Lindner and Jonathan U. Peled have published a review on the most current clinical and mouse studies of the microbiome and...

Pomalidomide in chronic GvHD – efficacy and safety

In this single-center, randomized phase II trial (NCT01688466), Lauren Curtis and colleagues investigate the safety and efficacy of pomalidomide in...

Practice-changing abstracts at ASCO and EHA 2020

Interview with GvHD Hub Co-Chair, Mohamad Mohty, providing an overview of the practice-changing abstracts from this year's virtual ASCO Annual Meeting...

Is arsenic trioxide effective in treating aGvHD? Results from an in vitro study

Xiao Liu and colleagues conducted a preclinical study to investigate the role of macrophage polarization in aGvHD and...

Can ruxolitinib be safely combined with regulatory T cells to enhance efficacy in treating cGVHD?

Virginia Escamilla Gómez and colleagues conducted a study to investigate whether adding Tregs to...

EHA 2020 | Phase III GRAVITAS-301 trial results on itacitinib plus corticosteroids for aGvHD

The results from the phase III GRAVITAS-301 trial that investigated the efficacy of the Janus kinase 1...